Featured Research

from universities, journals, and other organizations

HRGP (histadine-rich glycoprotein) modulates angiogenesis

Date:
March 25, 2010
Source:
American Journal of Pathology
Summary:
Scientists have identified HRGP as a new therapeutic target for anti-angiogenic cancer therapies.

Dr. Roy L Silverstein and colleagues of the Cleveland Clinic, Cleveland, OH have identified HRGP as a new therapeutic target for anti-angiogenic cancer therapies.

These results are presented in the April 2010 issue of the American Journal of Pathology.

Glioblastoma, which is the most common and aggressive form of brain tumor in humans, occurs in 2-3 per 100,000 people in the Europe and North America. Inhibiting angiogenesis, or new blood vessel growth, is a major therapeutic strategy for glioblastoma.

Interaction of CD36, a cell surface receptor expressed on the cells that line small blood vessels, with a secreted portion of brain angiogenesis inhibitor 1 (Vstat120) elicits an anti-angiogenic response. Klenotic et al discovered that Vstat120 binding to CD36 activated a pro-apoptotic (cell death-inducing) pathway, which could be blocked by HRGP through HRGP-Vstat120 binding. The HRGP-Vstat120 interaction restored endothelial cell migration and tube formation and increased brain tumor growth with corresponding increases in tumor blood vessel development. Indeed, HRGP expression levels were increased in human brain cancers, indicating that this angiogenic axis could provide a therapeutic target for anti-angiogenic cancer therapies.

The study by Klenotic et al suggests that "in conditions where neo-vasculature is poorly organized and "leaky," such as in tumor beds, or where platelet activation occurs, such as in a wound or inflammatory site, HRGP can accumulate in the extracellular matrix and abrogate the potent anti-angiogenic activity of a broad class of angiogenesis inhibitors."


Story Source:

The above story is based on materials provided by American Journal of Pathology. Note: Materials may be edited for content and length.


Journal Reference:

  1. P. A. Klenotic, P. Huang, J. Palomo, B. Kaur, E. G. Van Meir, M. A. Vogelbaum, M. Febbraio, C. L. Gladson, R. L. Silverstein. Histidine-Rich Glycoprotein Modulates the Anti-Angiogenic Effects of Vasculostatin. American Journal Of Pathology, 2010; DOI: 10.2353/ajpath.2010.090782

Cite This Page:

American Journal of Pathology. "HRGP (histadine-rich glycoprotein) modulates angiogenesis." ScienceDaily. ScienceDaily, 25 March 2010. <www.sciencedaily.com/releases/2010/03/100325225615.htm>.
American Journal of Pathology. (2010, March 25). HRGP (histadine-rich glycoprotein) modulates angiogenesis. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/03/100325225615.htm
American Journal of Pathology. "HRGP (histadine-rich glycoprotein) modulates angiogenesis." ScienceDaily. www.sciencedaily.com/releases/2010/03/100325225615.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins